Open Orphan plc changed its name to hVIVO plc on 26 October 2022, learn more here.

Articles & Research
from hVIVO

How Human Challenge Trials Can Accelerate Vaccine Development

Rolling Reviews – a useful tool to speed up the regulatory review process

Rolling reviews have been in the media spotlight because of a global need to approve COVID-19 treatments and vaccines quickly. This article provides an overview of how rolling reviews work...

Hot Topics – Vaccine Solutions for Tropical Diseases

COVID-19, caused by the betacoronavirus SARSCoV-2, has emerged from a bat reservoir in temperate China, causing a global pandemic that has resulted in over 1.5 million deaths and 68 million...

Accelerated regulatory pathway for pandemic vaccines

Vaccines form an important part of the combat against the current COVID-19 health crisis. Getting a range of effective vaccines to the market quickly will be essential if we are...

ERS International Congress 2020 Presentation: Experimental Respiratory Syncytial Virus Infection in Adults 60-75 years

hVIVO's presentation during the ERS International Congress 2020 presentation about experimental RSV infection in adults 60-75 years.

Temporal relationships of cytokines, chemokines and cellular biomarkers during Human Rhinovirus (HRV) infection in asthmatics

hVIVO's presentation during the ERS International Congress 2019 presentation about temporal relationships of cytokines, chemokines and cellular biomarkers during HRV infection in asthmatics.

A Key Endpoint in Viral Challenge Models of Asthma Exacerbations

Human Rhinovirus (HRV) is reported to be a leading cause of up to 80% of asthma exacerbations. The viral pathway and associated immune responses represent a potential key therapeutic target...

Pre-existing NP specific T-cell response correlates with reduction of symptoms in a human influenza challenge model

hVIVO's presentation during the Options X conference in 2019 about pre-existing NP specific T-cell response correlates with reduction of symptoms in a human influenza challenge model.

The Human Viral Challenge Model with A/PERTH/16/2009 H3N2A systematic analysis from five clinical studies

The human viral challenge model is well established, safe and ideal to study influenza. It allows researchers to illuminate each step of the infection: baseline, peak and return to healthy....

hVIVO is Gold Sponsor and presenter at World Vaccine Congress, Washington DC, USA April 2019

WVC 2017, 14-17 April 2019, Renaissance Washington DC Downtown Hotel, Washington DC, USA hVIVO is proud to once again be a Gold Sponsor of the World Vaccine Congress 2019, a...